购物车
- 全部删除
- 您的购物车当前为空
PKM2-IN-6 (compound 7d) 是一种效果显著且具有口服活性的PKM2抑制剂,其IC50值仅为23 nM。该化合物能够在G2期引发细胞周期停滞和细胞凋亡 (apoptosis),并在mRNA水平上降低PKM1与PKM2的表达。此外,PKM2-IN-6展现了对抗癌的活性,特别是在三阴性乳腺癌的研究中显示出其治疗潜力。
PKM2-IN-6 (compound 7d) 是一种效果显著且具有口服活性的PKM2抑制剂,其IC50值仅为23 nM。该化合物能够在G2期引发细胞周期停滞和细胞凋亡 (apoptosis),并在mRNA水平上降低PKM1与PKM2的表达。此外,PKM2-IN-6展现了对抗癌的活性,特别是在三阴性乳腺癌的研究中显示出其治疗潜力。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
10 mg | 询价 | 10-14周 | |
50 mg | 询价 | 10-14周 |
产品描述 | PKM2-IN-6 (compound 7d) is a potent PKM2 inhibitor that can be administered orally and demonstrates an IC 50 value of 23 nM. It triggers apoptosis and causes cell cycle arrest in the G2 phase, while also reducing the mRNA levels of both PKM1 and PKM2. Additionally, PKM2-IN-6 exhibits anticancer properties and shows promise for research in triple-negative breast cancer [1]. |
体外活性 | PKM2-IN-6 (compound 7d)(0, 20, 40, 60, 80, 100 μM; 48 h)对COLO-205、A-549、MCF-7细胞显示细胞毒性,IC 50 值分别为18.33、47.00、19.80 μM [1]。PKM2-IN-6(14.38 μM; 48 h)诱导细胞凋亡和细胞周期停滞于G2期 [1]。PKM2-IN-6(14.38 μM; 24 h)在mRNA水平上显著降低PKM1和PKM2的表达 [1]。细胞毒性测定[1]:细胞系COLO-205、A-549、MCF-7;浓度0, 20, 40, 60, 80, 100 μM;孵育时间48 h;结果:显示对COLO-205、A-549、MCF-7细胞的IC 50 分别为18.33、47.00、19.80 μM。RT-PCR[1]:细胞系4T1细胞;浓度14.38 μM;孵育时间24 h;结果:显著降低PKM1和PKM2的mRNA表达。凋亡分析[1]:细胞系4T1细胞;浓度14.38 μM;孵育时间48 h;结果:2D培养中,存活细胞从对照组的82.64%降至5.44%,晚期凋亡细胞为50.32%,坏死细胞为44.08%;3D培养中,存活细胞从对照组的89.05%降至52.45%,晚期凋亡细胞为9.84%,坏死细胞为36.62%。 |
体内活性 | PKM2-IN-6, administered at doses of 25 and 50 mg/kg orally each day for three weeks, can reduce tumor volume and weight in female CD-1 nude mice (6-8 weeks) injected with 4T1-Red-FLuc cells [1]. |
分子量 | 322.38 |
分子式 | C17H14N4OS |
CAS No. | 771467-00-6 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.